Madopar (Benserazide, Levodopa)

Levodopa/Benserazide, the active ingredient in Madopar, is a Antiparkinson agent presented as an oral tablet formulation for oral use. It is used to manage the motor symptoms of Parkinson's disease and related Parkinsonian syndromes in adult patients. GNH USA supplies Madopar as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Madopar is an antiparkinson agent that targets dopaminergic pathways to improve motor function in Parkinsonian disorders.

Parkinson's disease: alleviates bradykinesia, rigidity and resting tremor. Parkinsonian syndrome: improves motor symptoms in secondary or drug‑induced parkinsonism. Levodopa‑responsive Parkinsonism: provides symptomatic relief of motor deficits.

Madopar may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Orthostatic hypotension - Dizziness or light‑headedness - Insomnia or vivid dreams - Dyskinesia (involuntary movements) - Dry mouth

Serious or Rare Side Effects: - Hallucinations or psychosis - Severe hypotension or syncope - Cardiac arrhythmias - Neuroleptic malignant syndrome - Severe allergic reactions (rash, swelling, anaphylaxis) - Persistent or worsening dyskinesia

When prescribing Madopar, clinicians should consider several safety measures. - Monitor blood pressure: watch for orthostatic changes, especially at treatment initiation. - Assess for dyskinesia: adjust dose if involuntary movements develop. - Review psychiatric history: be alert for hallucinations or psychosis. - Avoid abrupt discontinuation: taper under medical supervision to prevent withdrawal effects. - Store at ambient temperature: keep in the original pack, protect from moisture.

Madopar can interact with various medicines, requiring careful management.

Major Interactions (Avoid): - Non‑selective MAO inhibitors (e.g., phenelzine): risk of hypertensive crisis. - Antipsychotics that block D2 receptors: reduce therapeutic efficacy. - High‑dose irreversible MAO‑B inhibitors (e.g., selegiline): may precipitate severe hypertension.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood‑pressure lowering effect. - SSRIs or SNRIs: potential for serotonin syndrome. - Iron or calcium supplements: may decrease levodopa absorption. - High‑protein meals: can reduce levodopa bioavailability.